Jazz Pharmaceuticals Reprices $2.7 Billion Outstanding Balance of Term Loan Facility
Jazz Pharmaceuticals (JAZZ) said Monday it repriced the roughly $2.7 billion outstanding balance of its term loan facility, which is expected to yield annual interest savings of about $23 million.
Express News | Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes Due 2026
BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $172
BofA Securities analyst Jason Gerberry maintains $Jazz Pharmaceuticals(JAZZ.US)$ with a buy rating, and maintains the target price at $172.According to TipRanks data, the analyst has a success rate
Buy Rating Upheld for Jazz Pharmaceuticals Amidst Potential for Growth and Strategic Revaluation
Express News | Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings Trajectory Could Turn Positive as the Stock Climbs 5.5% This Past Week
As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret
How Is The Market Feeling About Jazz Pharmaceuticals?
Jazz Pharmaceuticals's (NYSE:JAZZ) short percent of float has risen 4.88% since its last report. The company recently reported that it has 2.68 million shares sold short, which is 5.59% of all
Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Cuts Target Price to $150
Morgan Stanley analyst Jeffrey Hung maintains $Jazz Pharmaceuticals(JAZZ.US)$ with a hold rating, and adjusts the target price from $160 to $150.According to TipRanks data, the analyst has a success
Jazz Pharmaceuticals (JAZZ) Receives a Hold From Morgan Stanley
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical
Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?
RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating
Jazz Pharmaceuticals (JAZZ) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $113 to $230.
Express News | Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
Express News | Jazz Pharmaceuticals PLC : RBC Cuts Target Price to $175 From $176
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
In the last three months, 7 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ), offering a diverse range of perspectives from bullish to bearish.Summarizing their recent assessments
Express News | UBS Maintains Neutral on Jazz Pharmaceuticals, Lowers Price Target to $113
UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Cuts Target Price to $113
UBS analyst Ashwani Verma maintains $Jazz Pharmaceuticals(JAZZ.US)$ with a hold rating, and adjusts the target price from $117 to $113.According to TipRanks data, the analyst has a success rate of 43.
Baird Sees Jazz Study Failure as Positive for Rival Praxis
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $154 to $210
On Jun 21, major Wall Street analysts update their ratings for $Jazz Pharmaceuticals(JAZZ.US)$, with price targets ranging from $154 to $210.BofA Securities analyst Jason Gerberry maintains with a buy
Jazz Pharmaceuticals' Essential Tremor Drug Falls Flat in Phase IIb Trial